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Can public policies and research institutions in African countries provide safe and useful genetically 
modified (GM) food crops? This is an urgent question, recognizing that advancing GM food crops can 
be difficult, affected by global debate, and various regulatory protocols. Reaching farmers has been 
achieved in several countries only for GM cotton for insect resistant while approvals for food and feed 
crops lag behind. To address this question, we identified and examined public research pipelines for 
GM crops in Egypt, Kenya, South Africa and Zimbabwe. Genetic transformation events are reported for 
21 crops. Findings are presented for events nearing final stages of development, analysis of the crops, 
traits and genes involved, and details regarding biosafety. The paper concludes with a summary 
offering various policies, institutional and regulatory suggestions. 
 





Over the past 10 to 15 years, scientists have applied new 
genetic technologies to a diverse range of crops. Many of 
these technologies hold promise for addressing 
productivity constraints faced by smallholder, resource-
poor farmers. This is accomplished by transforming local 
or foreign (imported) plant varieties to provide new 
opportunities for socioeconomically diverse farming 
systems. Public institutes in developing countries, which 
rely to various degrees on national, international and 
private partners, lead this research. 
Most studies regarding the impact of genetically 
modified (GM) crops have focused on commercial 
biotechnology products used primarily in four 
industrialized nations (Falck-Zepeda et al., 1999, 2000) 
[Genetic modification allows selected individual genes to 
be transferred from one organism into another, including 
genes from unrelated species. The technology can be 
used to promote a desirable crop character or to 
suppress an undesirable trait (Nuffield Council on 
Bioethics, 2003)]. This study focuses on GM crop 
pipelines from public research in 4 African countries: 
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essential information regarding GM crops under 
development, status of biosafety approvals, implications 
of genes to be deployed, distribution of seed or improved 
planting material, and the range of partnerships available.  
Currently, the number of GM crops that have been 
approved and are cultivated in the developing world is 
largely limited to insect-protected cotton in Argentina, 
China, India, Mexico, and South Africa. Virtually all of this 
improved seed is available from commercial providers, 
with the exception of China, where publicly developed 
seed is available as well (Huang et al., 2002). Growers in 
these countries include poor, smallholder farmers (Thirtle 
et al., 2003).  
One reason why the approval and use of insect-
protected cotton is widespread is that cotton is not a food 
crop, but rather used for fiber, oil and livestock meal. 
Consequently, most regulatory authorities in developing 
countries have found it easier to approve this crop 
because they are not required to assess food safety—an 
area in which few developing country regulatory 
authorities feel competent.  The exceptions to this are 
South Africa and the Philippines where assessments 
have been conducted. 
Much has been accomplished with the investments in 
public agricultural biotechnology research.  A study was 
implemented to assess the state of publicly developed 





2004). [In this context, publicly developed GM crops are 
those developed by public or national institutes, including 
universities, agricultural research organizations, or 
biotechnology institutes]. This research shows for African 
countries, that 13 public institutions have stably 
transformed 21 crops, incorporating a wide range of 
genes for insect, fungal, viral, and bacterial resistance; 
protein and quality improvements; herbicide tolerance, 
and salt and drought stress.  
However, the primary source of GM crops continues to 
be the private sector. Multinational companies lead in the 
development of GM technologies and, given the 
technology’s market potential, have invested significant 
resources in facilitating technologies through regulatory 
processes. With the exception of cotton in China, public 
research products lag behind. 
This study addresses these points by examining in 
detail GM food crops, with the inclusion of cotton since it 
is a valuable cash crop for some small-scale, resource-






This study highlights expectations and limitations on 
public GM crops and traits in Egypt, South Africa, 
Zimbabwe and Kenya, providing crop research data 
through 2003.  To ensure that relevant knowledge, 
experiences, and insight were captured in the study, an 
expert survey approach was used. Given the fact that the 
development of biotechnology products is knowledge and 
resource-intensive, the survey was directed to pre-
selected experts with unique expertise and knowledge 
due to their position and involvement in their countries. 
The study team analyzed the information and consulted 
further with scientific and research leaders in their 
respective countries. Collection of information was 
coordinated with key national research organizations. A 
methodology was developed for analysis. 
 
Experts collected data across five categories: 
 
1. Information Collection.  Continent, country and lead 
institutes provided details on GM crop development. 
Table 1 shows the total number of events included in 
the final assessment for each country [For this study, a 
single, unique transformation event represents a 
combination of crop, transgene, lead research institute, 
and the specific country of origin, thus recognizing both 
the transformation event and its institutional context].  
2. Description of crops under research, transgenes 
deployed, and the desired phenotypic trait. Crops were 
categorized and sorted following the FAOSTAT crop 
classification. Transgene data were gathered as 
specifically as possible for each gene, but in a few 
cases  such  detail  was  either  not  clear  or  listed   as  




         Table 1. Number of transformation events by country. 
 
Country Number of Events 
Egypt 17 
Kenya 4 








eflist).  Information was also collected for phenotypic 
trait expression. Where possible, detailed information at 
the gene level was obtained [Phenotypic traits were 
categorized as per USDA APHIS classification. 
“Phenotype/Phenotype Category - the nature of the 
introduced trait. Each is assigned a two-letter code 
which describes the category into which the trait falls, 
as determined by the Animal and Plant Health 
Inspection Service (APHIS)” See 
http://www.nbiap.vt.edu/biomon/datacat.cfm].  
3. Types of genetic resources used for transformation 
were reported to determine whether a public institution 
or private firm developed these resources, and whether 
their origin was local or foreign (imported). 
4. The relation between regulatory processes and GM 
research. To accomplish this, data were collected by 
regulatory stage, emphasizing the most advanced 
events possible. Four stages were used: experimental, 
confined field trial, scale-up, or commercial release. For 
experimental stage entries, experts were asked to 
identify only highly developed biotechnologies coming 
from laboratory, greenhouse, or glasshouse. 
5. The type of collaboration developed (if any), and plans 
for dissemination of research outputs.  Questions 
asked included the number of institutions involved, the 
type of collaboration developed and the plans for 
dissemination. The study team developed data 
collection and validation methodologies for information 
about specific countries, crops, and gene/technology 
combinations. This led to classification of data as 
unique transformation events3. Not all possible events 
are summarized here, as the study is designed to be 
illustrative of trends, not an attempt to capture each 
and every transformation event under testing or 
production in the participating countries.  
 
A very high standard for the laboratory/greenhouse 
stages was set, as we cannot account for all the 
technologies in the research pipeline, particularly before 
proof of concept has been presented. As such, the 
survey cannot measure the flow of technologies from one 
stage to the next, nor can it tell whether technologies are 
getting stuck in a particular stage. 




PIPELINES FOR GM CROPS AND TRANSGENES 
EMPLOYED  
 
To date, our research includes 54 transformation events 
from 13 scientific institutes in 4 countries (Table 1). 
These countries maintain an ongoing commitment to 
biotechnology research, supported by universities and 
agricultural research institutes with good laboratory and 
agronomic capacity.  
Transformation events organized by crop groups are 
shown in Figure 1. While transformation of cereals 
predominates, there are significant numbers of 
transformation events for vegetables, roots and tubers, 
and sugar, with each group representing a fairly diverse 
set of crop species. The greatest numbers of 
transformation events are for: maize (17.0 percent), 
potatoes (13.0 percent), with sugar and tomatoes at (11.0 
percent) each. 
The percentage distribution of events by phenotypic 
groups is presented in Figure 2. Virus and insect 
resistance cover over half of the 54 events surveyed, and 
interestingly for Africa none of the traits were stacked. 
 
 
ENSURING SAFETY IN THE FIELD 
 
To examine the relationship between the transgenic 
events reported above and biosafety regulations for GM 
crops, the survey proposed a well-defined set of 
regulatory stages to classify each product, especially 
regarding field-testing and advancement. Respondents 
were asked to indicate in what stage of regulation their 
respective events were most accurately placed.  
Events in the experimental stage contain stable 
research products derived from multiple generations, 
beginning in the laboratory and moving to the 
greenhouse or glasshouse. In this stage, the stable 
expression of the gene of interest is confirmed. In 
confined field trials, expression of traits remains stable in 
small-scale, single or multi-location confined trials. These 
trials are designed to mitigate any environmental damage 
by their containment, thus their regulatory standards are 
different from those established for subsequent stages. 
The scale-up stage occurs when products advance 
from confined trials to pre-commercial trials, requiring the 
ability to increase seed amounts, and larger areas for 
testing purposes. These tests may be conducted for 
environmental safety purposes, efficacy trials, or both. 
Finally, products are made available to farmers only after 
commercial release, through privately- or publicly-owned 
seed companies or other institutional mechanisms.  
The survey data show that a total of 38 events are at 
the experimental stage, while 15 are in confined trials, 
and 1 is awaiting a permit (Figure 3). South Africa is a 
clear leader in getting events into the field.  
In all research pipelines, technologies or products are 














































Figure 2. Transformation events distributed by phenotypic groups. 
AP- Agronomic Properties; BR- Bacterial Resistance; FR- Fungal 
Resistance; HT- Herbicide Tolerance; IR- Insect Resistance; PQ- 
Product Quality; VR- Virus Resistance. 
 
 
questions. However, in the case of GM crops, many 
countries have only interim guidelines or regulations in 
place, most of which do not allow for commercial 
approvals. Other countries, with commercial approval 
abilities, often lack confidence in their commercial 
decision-making. Such decisions are influenced by 
negative public opinion, pressure from anti-GM groups, 
and the current trade impasse over GM crops between 
the USA and Europe (Compés López and Carrau, 2002). 
There may also be physical limitations such as growers’ 
inability to produce adequate seed amounts for large 
scale testing or for food safety testing.  
Those events in the confined testing represent the most 
promising public research for GM crops (Figure 3). These  
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Lab / Greenhouse Confined field trial Permit pending
 




15 events will decline in number during their rigorous 
evaluation. However, the public sector cannot just 
monitor confined trials for safety and efficacy. It must also 
guarantee seed supplies to evaluate product 
performance on a large scale, and include experiments 
designed specifically for safety evaluation.  Larger tests 
could be done in partnership with private seed companies 
or with government seed production facilities. To 
accomplish this successfully, events should be identified 
as soon as possible, based on the most reliable field trial 
data possible.  
We do not know the number of initial transformation 
events required to reach the event records in Figure 3. 
Are the 15 events in confined testing, spread over many 
crops, traits and countries, sufficient to select superior 
GM material, increase seed, biosafety trials, and finally, 
advancement to commercial use? Implications of these 
numbers and ratios require analysis among participating 
countries and institutes. This would better allow institutes 
to assess their role from a development perspective and 




SAFETY, REGULATION, AND REQUIRED 
ASSESSMENTS  
 
The most important benefit of biosafety regulation is 
ensuring that biotechnologies deployed in a country are 
safe and effective. In addition, a well functioning 
regulatory system can instill confidence in the public that 
the risk assessment used to evaluate newer 
technologies, including biotechnologies, are science-
based, as presented under Article 15 and Annex III of the 
Cartagena Protocol on Biosafety (Convention on 
Biological Diversity (CBD) Secretariat 2000). While the 
Protocol provides a unifying approach to biosafety, it also 
states that the cost of the assessment is borne by the 
notifier (Article 15).  
For this reason, the study explores the benefits and 
costs of regulation, especially those relevant to public 
institutions providing GM crops in the developing world. 
These institutions have little combined experience as 
“notifiers” and are only just beginning to understand the 
safety costs associated with those required for research 
and development. As all participating institutes place 
safety paramount, they wish to understand costs to the 
notifier as well as to society. These may occur from 
opportunities lost if biotechnologies having a potentially 
high social value are not approved, and hence not able to 
provide its net benefits to society.  
To initiate the exploration of safety and the costs of 
biosafety regulations, Kenya and South Africa were able 
to give basic estimates of costs they face as they seek to 
fulfill safety requirements while developing their specific 
technologies and crops (Table 2). In reviewing this data, 
some preliminary findings became apparent. 
A study by Odhiambo (2002) estimated the cost for an 
insect resistant corn event in Kenya at US$ 160,000. The 
major component of which is the cost of containment 
structures. Quemada (2003) estimated that the total cost 
for the biosafety regulatory compliance of virus resistant 
potatoes in South Africa amounted to US$ 830,000.   
Little data exists in African regarding food safety testing 
needed for regulatory approval. While there were not 
many examples of such tests, the need for food safety 
information, the policy and regulatory decisions affecting 
these requirements, and the severe  lack  of  capacity  for  




   Table 2. Preliminary estimates of average per year per event costs of biosafety regulations for two African countries. 
 
Country Average per year regulatory Cost 
per Event (Million US$) 
Crops Source 
Kenya 0.16 Insect resistant maize Odhiambo (2002) 
South Africa1 0.83 Virus resistant potatoes Quemada (2003) 
 
1The data presented for South Africa is from a paper developed by Quemada (2003). Very preliminary data for South Africa was presented in 
the Next Harvest conference by Brink and Koch (2002). Estimate for South Africa’s virus resistant potatoes are for the total regulatory span. 
 
 




Gene group (as best 





AP   8 
AP Drought tolerance 6  
AP Salt Tolerance 2  
BR   1 
BR Antimicrobial peptides 1  
FR   7 
FR Glucanase, PGIP2 2  
FR 
b32, PGIP2 (VOPI), 
and other selected 
anti-fungal genes 1  
FR Chitinase 1  
FR Glucanase, PGIP3 1  
FR Grape resveratrol 1  
FR 
PGIP1 and PGIP2 - 
isolated at VOPI 1  
HT   4 
HT Pat 3  
HT EPSPS 1  
IR   11 
IR Bt 11  
PQ   5 
PQ Higher sucrose 2  
PQ Nutritional 1  
PQ Confidential 1  
PQ Ethylene regulation 1  
VR   18 
VR Coat protein 15  
VR Replicase 2  
VR Antisense to TYLCV 1  
   54 
 
AP- Agronomic Properties; BR- Bacterial Resistance; FR- Fungal 
Resistance; HT- Herbicide Tolerance; IR- Insect Resistance; PQ- 
Product Quality; VR- Virus Resistance. 
 
 
such in developing countries was also discussed (Cohen 
et al., 2003). For this reason, among others, the 
Cartagena Biosafety Protocol envisions the need for 
capacity building among regulatory bodies as a central 
activity (CBD, 2001). 
These estimates rely on the state of knowledge and the 
current biosafety regulatory system in the respective 
countries as presented during the first Next Harvest 
conference in 2002. As knowledge, experiences, and 
exchange of information continue to grow, increased 
familiarity with GM technologies will enable regulatory 
agencies to have confidence to reduce requirements, 
thereby decreasing the approval costs per event.  
Participants noted that there has been a shift of 
regulatory costs to earlier stages of the research process.  
This fact highlights the need to rationalize GM research 
efforts by being more selective as to projects and 
numbers of events so that safety requirements can be 
completed. Participants also noted the importance of 
ensuring that the cost structure and level of regulatory 
processes are adequate to assure safety, while not 




PHENOTYPES AND TRANSGENES 
 
Specific transgenes or gene groups were identified and 
classified according to the phenotype expressed. This 
allows comparisons of regulatory information available 
and expected for genes in wide use, or those that are 
more unique. The entire set of 54 events are grouped 
under 7 phenotypic groups, (Table 3) of which virus 
resistance has the highest entries with 18, followed by 11 
for insect resistance, 8 for agronomic performance and 7 
for fungal resistance.   
Worldwide, there are primarily three gene groups with 
sufficiently robust utility and suitability for wide use, and 
those are Cry genes from Bacillus thuringiensis (Bt 
genes) that provide insect resistance, coat protein genes 
for virus resistance and thirdly those genes conferring 
herbicide tolerance. Interestingly for Africa, the first gene 
group consists of coat proteins of plant viruses used for 
virus resistance. The second group consists of Bt genes 
for insect resistance, and the third group consists of 
genes conferring agronomic performance. Most other 
gene groups and their associated phenotypic traits have 
not yet demonstrated robust applicability in the field. For 
example, no gene group has yet to confer effective fungal 
resistance, although much experimental activity has been 
spent on investigating the glucanases and chitinases. For 
Africa this group represented 7 entries alone.  




                                Table 4. Distribution of phenotypic traits by country.  
 
AP BR FR HT IR PQ VR Total 
Continent 
  Crops 
(number) Number of events 
Egypt 8 4  1  2  10 17 
Kenya 2    1 2  1 4 
South Africa 7 4 1 6 3 5 5 4 28 
Zimbabwe 3     2  3 5 
 All 20 8 1 7 4 11 5 18 54 
 
AP- Agronomic Properties; BR- Bacterial Resistance; FR- Fungal Resistance; HT- Herbicide Tolerance; 
IR- Insect Resistance; PQ- Product Quality; VR- Virus Resistance. 
 
 
Similarly, no group of genes has been shown to reliably 
confer bacterial resistance in the field, even though many 
investigators have studied the effects of antimicrobial 
peptides, globally, and in Africa only one such event was 
recorded.  While herbicide tolerance ranks third 
worldwide, it only ranked sixth for Africa, reflecting a 
totally different trend that might be linked to either the 
cost of the herbicides on the continent or indeed a 
cultural reason such as the fact that weeding is primarily 
carried out by women, and therefore few resources are 
devoted to this task. An emerging group of traits for Africa 
is drought tolerance leading at 6 events and 2 for salt 
tolerance. Thus, there is only limited success in 
developing crops with traits other than insect resistance, 
virus resistance, and agronomic performance. The large 
number of single gene approaches means that 
researchers are testing numerous alternatives to achieve 
traits of interest, which may lead to identifying utility of 
other gene groups.  This trend could be a reflection of 
Africa’s diverse ecology and culture.  
One gene for product quality was labeled as 
confidential. Such confidentiality indicates that countries 
are becoming aware of the need to protect intellectual 
property rights in the earlier stages of development. 
These confidential genes could be publicly developed or 
received from the private sector under confidential 
agreements.  
When developing country scientists use genes made 
available for research, licensed, or derived from 
collaborative research, greater amounts of data are 
available to enable regulatory decisions. The more 
unique the gene and crop used for transformation, the 
additional data that will be required during the biosafety 
review, as well as having fewer options to benefit from 
other sources.   
Among the genes or gene groups listed below, the Cry 
genes, coat protein genes, and herbicide tolerance genes 
can be expected to move through regulation with fewer 
requirements for additional data. This is because 
numerous safety reviews have been conducted on these 
genes in several countries. However, this does not rule 
out the need for tests to address specific environmental, 
cultural or biodiversity concerns, as results of such  tests  
may not be transferable from one country to another. 
OTHER FINDINGS 
 
By continent, researchers in four African countries 
(including North and Sub-Saharan Africa) completed 54 
events. While research is underway in the 4 countries 
surveyed, with the exception of South Africa and Egypt, 
the rest of Africa is seriously lacking in capabilities and 
resources to consider such research (Alhassan 2003; UN 
ECA 2002), and in many cases, countries are just 
exploring the implications whether to consider research 
on, or import of, GM crops. Research capacity and 
potential markets are evolving (such as insect resistant 
cotton), albeit subject to uncertainties regarding the use 
and trade of GM crops.  
As shown in Table 4 below, Egypt conducts research 
on the largest variety of crops, followed closely by South 
Africa. South Africa however has the largest variety of 
events, compared to Egypt. Bacterial resistance is the 
most limited, while the single most important group is the 
expression of virus resistance. As will be discussed later, 
such commonalities could lead to new forms of 
collaboration among neighboring countries, including new 
opportunities for exchanging transgenes and germplasm. 
The leading countries could help build capacity by 
providing training, shared experiences and enhance 
south-south collaboration. 
 
South Africa presents an important case study. South 
Africa has devoted an appreciable amount of money to 
biotechnology research and development. Though the 
South African research program was relatively 
unfocussed in its early years, it has become more 
targeted and better coordinated with the enactment of the 
Biotechnology Strategic Plan and the BRICS 
(Biotechnology Research Innovation Centers), and under 
the pressure of reduced financial support for research in 
the Agricultural Research Council.  
Furthermore South Africa’s requirement that research 
proposals be linked to industrial applications or 
development partners is ensuring that agbiotech products 
are developed with relevance for end-users. More 
recently, the government initiated a three-year program to 
improve Public Understanding of Biotechnology 
(http://www.pub.ac.za/) that promotes  informed  decision 




making among the population (Koch, personal 
communication 2004). South Africa has an established 
biosafety process that reviews all activities with GMOs 
and has recently ratified the Cartagena Protocol on 
Biosafety.   
While South African research was somewhat 
unfocused in its early years, the research reported here 
for Egypt appears focused and clearly targeted for key 
crops, and a whole variety of traits being exploited. A 
large number of products are in advanced trials.  Egypt 
has clearly benefited from the collaboration with the 
private sector as well as the Agricultural Biotechnology 
Support Program in phase I (ABSP I).  
Zimbabwe has a highly developed seed sector, a 
functional biosafety regulatory system that should lend 
itself well to the arrival of GM technologies. Zimbabwe 
has signed the Cartagena Protocol on Biosafety and the 
ratification process is well underway. The country 
however does not have a clear policy on GMOs, although 
plans are underway in the legal fraternity to mount a 
national policy dialogue on the subject. 
Establishment of a fully functional biosafety regulatory 
system in Kenya is well underway. In recent years Kenya 
has enjoyed excellent partnerships on several different 
fronts, including the hosting of the African Agricultural 
Technology Foundation (AATF) a foundation established 
to broker royalty-free technology transfer from the private 
sector to research institutions and resource poor farmers 
in sub-Saharan Africa, as well as the launch of a Center 
of Excellence, the Biosciences Center for East and 
Central Africa (BECA) under the New Partnership for 
African Development (NEPAD). Collaboration with both 
Monsanto Company for the virus resistant sweet potato 
and with the Syngenta Foundation on the insect resistant 
maize for Africa (IRMA) has brought much needed 
capacity to the Kenya Agricultural Research Institute 
(KARI). These projects have helped Kenya build strong 
capacity in biosafety reviews and infrastructure. 
 The presence of a functional seed development and 
delivery system cannot be overemphasized. In many 
African countries, such stable, market-oriented, and seed 
distribution networks barely exist, or do not exist at all, 
creating almost sole dependence on the public sector for 
agricultural innovation. This is especially true for 
countries not allowing import, testing and possible 
approval of commercial transgenic crops. With sole 
dependence on public sector, and no ability to import GM 






Will policies and research in the developing world 
stimulate the safe use of publicly developed GM food 
crops? We addressed this question with an analysis that 





continent, and from genes and crops used for 
transformation. To do so, the paper summarized 
information for GM crop research conducted by public 
research institutes in 4 African countries. This information 
will help scientists, policy makers, and regulators 
understand their respective countries’ public GM 
research and help address the question above. Further 
analysis—more in-depth and specialized examination of 
the key issues— will be conducted in direct consultation 
with the participating countries.  
Research institutes covered in this study demonstrate 
capabilities across 21 plants, several different 
phenotypes, and the ability to use transgenes together 
with available genetic resources. In so doing, scientists 
have harnessed an assortment of genes in pursuit of 
traits relevant to farmers. Some have also gained 
familiarity with regulatory dossiers as needed for 
biosafety determinations. The range and diversity of 
these crops is wide, exceeding that carried out through 
international programs. However, desired phenotypes are 
few when compared to traits being developed by 
multinational firms or advanced research institutes in 
industrialized countries (Nuffield Council on Bioethics, 
2004). 
The public sector is a viable, but largely unproven, 
player in the bioengineering of local crops.  While on the 
policy front, regulatory systems and policies have been 
under development for over 10 years in Africa. Some of 
these systems have already conducted biosafety 
assessments, and have determined which crops are 
acceptable for trials and use. However, even with this 
progress, regulatory decision-making remains 
complicated, affected by conforming to the Cartagena 
Protocol for Biosafety, and, are subject to delays or 
moratoria. The fact that there are approximately 39 
percent of the 38 events in various phases of confined 
testing indicates opportunities for advancement of public 
sector research products. However, the longer the 
waiting period, the more likely the trait and or germplasm 
becomes ineffective as disease pressures change and 
more productive varieties are released.   
The need for “single window” approaches for regulatory 
authorities and committees was noted to minimize time 
delays for approvals, thus making public sector research 
more efficient (Atanassov et al., 2004). Limited human 
resources also mean that, in certain cases, the 
developers of the technology are also the regulators, 
raising questions of conflict of interest which could further 
cloud the issue of acceptability and transparency. 
A combined policy/institutional issue also arises for 
public GM crops because so many institutes work alone, 
without research or development partners. The data and 
analysis presented here can reduce such isolation by 
finding commonalities among crops, genes, regulatory 
stages, and collaboration. With this information, private 
firms and public research institutes can pursue greater 






Moreover, this information can be used to organize 
greater South-to-South collaboration, a mode of 
partnership that does not presently exist in any 
appreciable quantity. Greater South-South collaboration 
will provide one more way to strengthen inter-institutional 
research and experiences. This can occur by building on 
common approaches, genes, and stage of regulatory 
trials and required safety information.  
The information reviewed in this study can also inform 
readers of parallel research in their own country, in other 
regions, and internationally. This can be valuable when 
selecting transgenes, considering regulatory 
requirements, and genetic resources available, or 
needed.   
Building on these new opportunities to strengthen 
public GM crop research and exchange experiences, 
does not mean that all decisions are in the researcher’s 
hands alone. Rather, it is a process involving several 
policy dimensions concerning the regulatory system, the 
political and trade environment, the management of 
development opportunities and partnerships, and keeping 
in constant dialogue with farmers to address their needs 
and the needs of specific communities.  
However, all of these events and policies can also be 
used against the very technologies they are there to 
evaluate and to advance once proven. Delays can mean 
rising costs, lack of impact at the rural level, regulatory 
requirements in need of clarification, and more direct 
accountability. Such concerns are emerging issues in 
developing countries. The combined effect is delayed 
impact and uncertainty of the technologies, both of which 
are used by biotechnology’s detractors nationally and 
internationally.  
We have recognized policy, political and institutional 
changes where efficiencies could be gained, while 
supporting the need for safety and efficacy testing of GM 
crops. A combination of these changes and farmer 
testing of products from public research means a rapid 
assessment of success or failure. Clearly immense 
progress has been made on all fronts; but efforts are still 
needed to ensure that polices and institutes in the 
developing world stimulate the safe and relevant use of 
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